Hypoglycemia and Autonomic Nervous System Function-B

• Status: Active, not recruiting
• Trial end date: 2022-01-04
• Target enrollment: 0
• Participant gender: All

Summary

This study tests the hypothesis that, compared to prior normal blood sugar, prior low blood sugar impairs cardiovascular autonomic function. The proposed studies will also test the hypothesis that the effects of prior low blood sugar on cardiovascular autonomic function are blocked by administration of a mineralocorticoid receptor antagonist.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborators: Beth Israel Deaconess Medical Center; National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Hypoglycemic Agents; Spironolactone

Criteria

Inclusion Criteria:

• Healthy volunteers

• Males and females age 18 to 55 years

Exclusion Criteria:

• Pregnancy

• Lactation

• Clinically evident coronary artery, cerebrovascular, or peripheral vascular disease, or presence of systemic illness that might affect autonomic function. Such illnesses include diabetes mellitus, congestive heart failure, hypertension, renal, pulmonary, hepatic disease, anemia, malignancies, untreated thyroid disease, and alcoholism.

• Current major depressive illness

• In all subjects, any individuals on oral, injected, inhaled or topical corticosteroids within the last year or oral contraceptives within the past 3 months will be excluded.

• Use of medications other than thyroxine

• Known hypersensitivity to nitroglycerin, nitroprusside and/or phenylephrine.

• Blood pressure > 140/90 mmHg

• Creatinine > 1.5 mg/dL

• Serum potassium >5.2 mmol/L

• Estimated GFR < 50 mL/min

• Use of Viagra, Cialis, and similar drugs within 72 hours of admission.